PDL BioPharma Inc. Review of 3Q 2016 Results and Forward Outlook

NEW YORK, NY / ACCESSWIRE / January 31, 2017 / Traders News Source, an equity research firm specializing in small and micro-cap securities, is looking at recent events with PDL BioPharma Inc. (NASDAQ: PDLI). It derives most of its revenue from licensing royalties and patents. PDL announced results for the third quarter on November 3rd, 2016, which was lower than consensus expectations. The company reported revenue of $53.6M, which declined over 57% on a YoY basis, mainly due to continued expiration in long term royalty agreements. The company is attempting to revive itself by providing financing at favorable terms to smaller companies that are working on promising healthcare solutions.

Our full report looks at the steps PDLI could take to recoup falling
revenues READ HERE

(Copy and paste to your browser may be required- http://bit.ly/2joBATr-PDLI-Report)

In the recent past, PDL has emerged as a healthcare-focused finance company & is focusing on investing in royalty streams, providing high-yield financing to life science companies with near-term product launches as well as through purchase of approved drugs to be sold on a high margin basis. This allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. The company has investments in a few royalty and debt investments. PDL completed its first equity transactions in July 2016 with Noden Pharma DAC. Noden Pharma is a specialty pharmaceutical company based in Dublin, Ireland, and with affiliated U.S. operations. It focuses on acquiring and optimizing established medicines.

What near term events might impact the stock
price of PDLI? Read our full report READ HERE

(Copy and paste to your browser may be required- http://bit.ly/2joBATr-PDLI-Report)

DISCLOSURE

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agarwal a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email between 09:30 EST to 16:00 EST from Monday through Friday at: editor@tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

ReleaseID: 453895